Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tryptoline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A known ✓ | P47898 | 1/20 | 0.96 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.74 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.74 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.55 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.55 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.55 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.55 |
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.46 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.96 |
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.96 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tryptoline SCHEMBL8818317 | 1.00 | NISCH (0.96) | NISCHKDM4ENR2E1HTR5ATAAR1 | |
| Tryptoline SCHEMBL9480983 | 0.98 | NISCH (1.00) | NISCHKDM4ENR2E1HTR5ATAAR1 | |
| Tryptoline SCHEMBL29350043 | 0.98 | NISCH (1.00) | NISCHKDM4ENR2E1HTR5ATAAR1 | |
| Tryptoline SCHEMBL12190178 | 0.98 | NISCH (1.00) | NISCHKDM4ENR2E1HTR5ATAAR1 | |
| Tryptoline SCHEMBL9754749 | 0.98 | NISCH (1.00) | NISCHKDM4ENR2E1HTR5ATAAR1 | |
| Tryptoline SCHEMBL171755 | 0.98 | NISCH (1.00) | NISCHKDM4ENR2E1HTR5ATAAR1 | |
| Tryptoline SCHEMBL28226558 | 0.96 | NISCH (0.96) | NISCHKDM4ENR2E1HTR5ATAAR1 | |
| Tryptoline SCHEMBL28477910 | 0.95 | NISCH (0.93) | NISCHKDM4ENR2E1HTR5ATAAR1 | |
| Tryptoline SCHEMBL28856564 | 0.92 | NISCH (0.82) | NISCHKDM4ENR2E1HTR5ATAAR1 | |
| Tryptoline SCHEMBL29139386 | 0.90 | NISCH (0.84) | NISCHKDM4ENR2E1HTR5ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256102-B1 | PEPTIDIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES OF SAID COMPOUNDS, IN PARTICULAR COSMETIC USES | SEDERMA SA (FR) | 2023-08-09 | — | — | EP | claimed |
| CN-118450890-A | Treatment of cancer and autoimmune disorders using nano-polymers of histone deacetylase inhibitors | 弗吉尼亚大学专利基金委员会 | 2024-08-06 | — | — | CN | disclosed |
| CN-118139614-A | Sterile liposome-containing compositions and articles | 脂肪球有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-111527065-B | Synthetic derivatives of oleoyl-lysophosphatidylinositol (oleoyl-LPI) and uses thereof | 科廷大学 | 2024-05-07 | — | — | CN | disclosed |
| CN-110678543-B | In vitro culture system and method of use thereof | 耶达研究及发展有限公司 | 2024-04-09 | — | — | CN | disclosed |
| WO-2024015406-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-01-18 | — | — | WO | disclosed |
| CN-117280030-A | Agents, compositions and methods for treating hypoxia and ischemia related conditions | 梅兰德制药公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-117098517-A | Drug eluting stent | 赛诺医疗科学技术股份有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-110612097-B | Liposome drug delivery vehicle | 耶达研究及发展有限公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-3256102-B1 | PEPTIDIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES OF SAID COMPOUNDS, IN PARTICULAR COSMETIC USES | SEDERMA SA (FR) | 2023-08-09 | — | — | EP | disclosed |
| US-11612556-B2 | Peptidic compounds, compositions comprising them and uses of said compounds, in particular cosmetic uses | SEDERMA (FR) | 2023-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612556-B2 | Peptidic compounds, compositions comprising them and uses of said compounds, in particular cosmetic uses | PLOD1, COL1A1, PLOD2 | HTR5A 1298/4885HTR2A 3589/4885HTR2C 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.